Resistance trends of Bacteroides fragilis group over an 8-Year Period, 1997-2004, in Korea

Kyoung Ho Roh, Sinyoung Kim, Chang Ki Kim, Jong Hwa Yum, Myung Sook Kim, Dongeun Yong, Kyungwon Lee, June Myung Kim, Yunsop Chong

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Bacteroides fragilis group organisms are the most frequently isolated anaerobes in human infections. Increasing resistance to various antimicrobial agents is a significant problem in choosing appropriate antimicrobial agents to treat anaerobic infections. Periodic monitoring of the regional resistance trends of B. fragilis group isolates is needed. Methods: A total of 466 nonduplicate clinical isolates of B. fragilis group organisms (276 B. fragilis, 106 Bacteroides thetaiotaomicron, and 84 other B. fragilis group organisms) were collected during the 8-yr period from 1997 to 2004 in a Korean university hospital. Minimum inhibitory concentrations to various antimicrobial agents were determined by the CLSI agar dilution method. Results: Eight isolates were resistant to imipenem. Additionally, the resistance rates to cefotetan were decreased in B. thetaiotaomicron, while those for clindamycin were significantly increased compared to the rates found in previous studies. Depending on species, resistance rates were 1-4% for imipenem, 1-6% for piperacillin-tazobactam, 4-11% for cefoxitin, 33-49% for piperacillin, 14-60% for cefotetan, and 51-76% for clindamycin. No isolates were resistant to chloramphenicol or metron-idazole. Conclusions: Piperacillin-tazobactam, cefoxitin, imipenem, chloramphenicol, and metronidazole are still active against B. fragilis group isolates, while clindamycin no longer has a value as an empirical therapeutic agent in Korea. Furthermore, this study identified the first imipenem-resistant B. fragilis group isolates in Korea.

Original languageEnglish
Pages (from-to)293-298
Number of pages6
JournalKorean Journal of Laboratory Medicine
Volume29
Issue number4
DOIs
Publication statusPublished - 2009 Dec 1

Fingerprint

Bacteroides fragilis
Imipenem
Korea
Clindamycin
Anti-Infective Agents
Cefotetan
Cefoxitin
Chloramphenicol
Piperacillin
Metronidazole
Dilution
Agar
Microbial Sensitivity Tests
Infection
Monitoring
tazobactam drug combination piperacillin

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Roh, Kyoung Ho ; Kim, Sinyoung ; Kim, Chang Ki ; Yum, Jong Hwa ; Kim, Myung Sook ; Yong, Dongeun ; Lee, Kyungwon ; Kim, June Myung ; Chong, Yunsop. / Resistance trends of Bacteroides fragilis group over an 8-Year Period, 1997-2004, in Korea. In: Korean Journal of Laboratory Medicine. 2009 ; Vol. 29, No. 4. pp. 293-298.
@article{20d4b7ad8b9443fd95a6d0d45a03c1f7,
title = "Resistance trends of Bacteroides fragilis group over an 8-Year Period, 1997-2004, in Korea",
abstract = "Background: Bacteroides fragilis group organisms are the most frequently isolated anaerobes in human infections. Increasing resistance to various antimicrobial agents is a significant problem in choosing appropriate antimicrobial agents to treat anaerobic infections. Periodic monitoring of the regional resistance trends of B. fragilis group isolates is needed. Methods: A total of 466 nonduplicate clinical isolates of B. fragilis group organisms (276 B. fragilis, 106 Bacteroides thetaiotaomicron, and 84 other B. fragilis group organisms) were collected during the 8-yr period from 1997 to 2004 in a Korean university hospital. Minimum inhibitory concentrations to various antimicrobial agents were determined by the CLSI agar dilution method. Results: Eight isolates were resistant to imipenem. Additionally, the resistance rates to cefotetan were decreased in B. thetaiotaomicron, while those for clindamycin were significantly increased compared to the rates found in previous studies. Depending on species, resistance rates were 1-4{\%} for imipenem, 1-6{\%} for piperacillin-tazobactam, 4-11{\%} for cefoxitin, 33-49{\%} for piperacillin, 14-60{\%} for cefotetan, and 51-76{\%} for clindamycin. No isolates were resistant to chloramphenicol or metron-idazole. Conclusions: Piperacillin-tazobactam, cefoxitin, imipenem, chloramphenicol, and metronidazole are still active against B. fragilis group isolates, while clindamycin no longer has a value as an empirical therapeutic agent in Korea. Furthermore, this study identified the first imipenem-resistant B. fragilis group isolates in Korea.",
author = "Roh, {Kyoung Ho} and Sinyoung Kim and Kim, {Chang Ki} and Yum, {Jong Hwa} and Kim, {Myung Sook} and Dongeun Yong and Kyungwon Lee and Kim, {June Myung} and Yunsop Chong",
year = "2009",
month = "12",
day = "1",
doi = "10.3343/kjlm.2009.29.4.293",
language = "English",
volume = "29",
pages = "293--298",
journal = "Annals of Laboratory Medicine",
issn = "2234-3806",
publisher = "Seoul National University",
number = "4",

}

Resistance trends of Bacteroides fragilis group over an 8-Year Period, 1997-2004, in Korea. / Roh, Kyoung Ho; Kim, Sinyoung; Kim, Chang Ki; Yum, Jong Hwa; Kim, Myung Sook; Yong, Dongeun; Lee, Kyungwon; Kim, June Myung; Chong, Yunsop.

In: Korean Journal of Laboratory Medicine, Vol. 29, No. 4, 01.12.2009, p. 293-298.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Resistance trends of Bacteroides fragilis group over an 8-Year Period, 1997-2004, in Korea

AU - Roh, Kyoung Ho

AU - Kim, Sinyoung

AU - Kim, Chang Ki

AU - Yum, Jong Hwa

AU - Kim, Myung Sook

AU - Yong, Dongeun

AU - Lee, Kyungwon

AU - Kim, June Myung

AU - Chong, Yunsop

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Background: Bacteroides fragilis group organisms are the most frequently isolated anaerobes in human infections. Increasing resistance to various antimicrobial agents is a significant problem in choosing appropriate antimicrobial agents to treat anaerobic infections. Periodic monitoring of the regional resistance trends of B. fragilis group isolates is needed. Methods: A total of 466 nonduplicate clinical isolates of B. fragilis group organisms (276 B. fragilis, 106 Bacteroides thetaiotaomicron, and 84 other B. fragilis group organisms) were collected during the 8-yr period from 1997 to 2004 in a Korean university hospital. Minimum inhibitory concentrations to various antimicrobial agents were determined by the CLSI agar dilution method. Results: Eight isolates were resistant to imipenem. Additionally, the resistance rates to cefotetan were decreased in B. thetaiotaomicron, while those for clindamycin were significantly increased compared to the rates found in previous studies. Depending on species, resistance rates were 1-4% for imipenem, 1-6% for piperacillin-tazobactam, 4-11% for cefoxitin, 33-49% for piperacillin, 14-60% for cefotetan, and 51-76% for clindamycin. No isolates were resistant to chloramphenicol or metron-idazole. Conclusions: Piperacillin-tazobactam, cefoxitin, imipenem, chloramphenicol, and metronidazole are still active against B. fragilis group isolates, while clindamycin no longer has a value as an empirical therapeutic agent in Korea. Furthermore, this study identified the first imipenem-resistant B. fragilis group isolates in Korea.

AB - Background: Bacteroides fragilis group organisms are the most frequently isolated anaerobes in human infections. Increasing resistance to various antimicrobial agents is a significant problem in choosing appropriate antimicrobial agents to treat anaerobic infections. Periodic monitoring of the regional resistance trends of B. fragilis group isolates is needed. Methods: A total of 466 nonduplicate clinical isolates of B. fragilis group organisms (276 B. fragilis, 106 Bacteroides thetaiotaomicron, and 84 other B. fragilis group organisms) were collected during the 8-yr period from 1997 to 2004 in a Korean university hospital. Minimum inhibitory concentrations to various antimicrobial agents were determined by the CLSI agar dilution method. Results: Eight isolates were resistant to imipenem. Additionally, the resistance rates to cefotetan were decreased in B. thetaiotaomicron, while those for clindamycin were significantly increased compared to the rates found in previous studies. Depending on species, resistance rates were 1-4% for imipenem, 1-6% for piperacillin-tazobactam, 4-11% for cefoxitin, 33-49% for piperacillin, 14-60% for cefotetan, and 51-76% for clindamycin. No isolates were resistant to chloramphenicol or metron-idazole. Conclusions: Piperacillin-tazobactam, cefoxitin, imipenem, chloramphenicol, and metronidazole are still active against B. fragilis group isolates, while clindamycin no longer has a value as an empirical therapeutic agent in Korea. Furthermore, this study identified the first imipenem-resistant B. fragilis group isolates in Korea.

UR - http://www.scopus.com/inward/record.url?scp=73349102191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349102191&partnerID=8YFLogxK

U2 - 10.3343/kjlm.2009.29.4.293

DO - 10.3343/kjlm.2009.29.4.293

M3 - Article

C2 - 19726890

AN - SCOPUS:73349102191

VL - 29

SP - 293

EP - 298

JO - Annals of Laboratory Medicine

JF - Annals of Laboratory Medicine

SN - 2234-3806

IS - 4

ER -